Drug news
Actos (Takeda) US patent expires and Ranbaxy launches generic for Type 2 Diabetes.
The patent has expired in the United States for Actos (pioglitazone)for the treatment of Type 2 Diabetes from Takeda. Ranbaxy will launch a generic now with 180 days exclusivity and with other generic companies to follow ,including Mylan. Actos represented 51.8% of Takeda US revenue and 18% of its total revenue.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.